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Abstract
Aims/hypothesis Hyperproinsulinaemia and relative hyperglu-
cagonaemia are features of type 2 diabetes. We hypothesised
that raised fasting glucagon and proinsulin concentrations
may be associated with insulin resistance (IR) in non-diabetic
individuals.
Methods We measured IR [by a euglycaemic–hyperinsuli-
naemic (240 pmol min−1 m−2) clamp technique] in 1,296
non-diabetic (on a 75 g OGTT) individuals [716 women and
579 men, mean age 44 years, BMI 26 kg/m2 (range 18–
44 kg/m2)] recruited at 19 centres in 14 European countries.
IR was related to fasting proinsulin or pancreatic glucagon
concentrations in univariate and multivariate analyses.
Given its known relationship to IR, serum adiponectin was
used as a positive control.
Results In either sex, both glucagon and proinsulin were
directly related to IR, while adiponectin was negatively
associated with it (all p<0.0001). In multivariate models,
controlling for known determinants of insulin sensitivity
(i.e. sex, age, BMI and glucose tolerance) as well as factors
potentially affecting glucagon and proinsulin (i.e. fasting
plasma glucose and C-peptide concentrations), glucagon and
proinsulin were still positively associated, and adiponectin
was negatively associated, with IR. Finally, when these
associations were tested as the probability that individuals in
the top IR quartile would have hormone levels in the top
quartile of their distribution independently of covariates,
the odds ratio was ∼2 for both glucagon (p=0.05) and
proinsulin (p=0.02) and 0.36 for adiponectin (p<0.0001).
Conclusions/interpretation Whole-body IR is independent-
ly associated with raised fasting plasma glucagon and
proinsulin concentrations, possibly as a result of IR at the
level of alpha cells and beta cells in pancreatic islets.
Keywords Adiponectin . Alpha cell dysfunction . Beta cell
dysfunction . Glucagon . Insulin resistance . Proinsulin
Abbreviations
FFM fat-free mass
IFG impaired fasting glycaemia
IGR impaired glucose regulation
IGT impaired glucose tolerance
IR insulin resistance
NGT normal glucose tolerance
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Introduction
Day-long plasma glucagon concentrations are raised in
patients with type 2 diabetes [1]. Impaired suppression of
glucagon release can be detected in individuals with impaired
glucose tolerance (IGT) and type 2 diabetes following
intravenous [2] or oral glucose administration [3]. Fasting
glucagon concentrations exert a tonic stimulatory influence
on hepatic glucose output, which in the dog has been esti-
mated to account for one-third of the fasting rate of glucose
release [4]. Thus, under fasting conditions hyperglucagonaemia
sustains glucose overproduction [4], and impaired glucagon
suppression after oral glucose or a mixed meal contributes
to the postprandial hyperglycaemia of type 2 diabetes [3].
Previous studies in postmenopausal women with IGT [5] or
normal glucose tolerance (NGT) [6] have reported an in-
verse association between arginine-induced glucagon release
and insulin sensitivity. Whether such a relationship extends
to women and men of any age and body weight has not
been determined.
Elevated fasting proinsulin concentrations, or their ratios
to the fasting insulin level, have long been known to occur
in states of impaired glucose regulation (IGR) [7–9] and to
predict incident diabetes [10, 11]. This finding is generally
interpreted as a sign of beta cell dysfunction, possibly
related to defective processing of the pro-hormone, prefer-
ential release of newly synthesised proinsulin or the release
of immature proinsulin-rich granules [12, 13]. Although
hyperproinsulinaemia has been generally described in
conditions characterised by insulin resistance (IR), whether
it reflects, or is related to, IR in non-diabetic individuals has
not been investigated.
In the present study, we have sought evidence for an
independent association of fasting glucagon and proinsulin
concentrations with IR (as a post hoc hypothesis) in a
large cohort of non-diabetic men and women in whom
insulin sensitivity was measured with the euglycaemic–
hyperinsulinaemic clamp technique.
Methods
Study participants The Relationship Between Insulin Sen-
sitivity and Cardiovascular Disease Risk (RISC) study is a
prospective, observational cohort study whose rationale and
methodology have been published [14]. In brief, partic-
ipants were recruited from the local population at 19 centres
in 14 countries in Europe, according to the following inclu-
sion criteria: men and women, age between 30–60 years and
clinically healthy. Initial exclusion criteria were: treatment
for obesity, hypertension, lipid disorders or diabetes, preg-
nancy, cardiovascular or chronic lung disease, weight
change of ≥5 kg in the last 6 months, cancer (in the last
5 years) and renal failure. Exclusion criteria after screening
were: arterial blood pressure ≥140/90 mmHg, fasting plasma
glucose ≥7.0 mmol/l, 2 h plasma glucose (on a 75 g OGTT)
≥11.0 mmol/l, total serum cholesterol ≥7.8 mmol/l, serum
triacylglycerol ≥4.6 mmol/l and ECG abnormalities. Baseline
examinations began in June 2002 and were completed in
November 2004. The present analysis is based on the 1,296
individuals [716 women and 580 men, mean age 44 years,
BMI 26 kg/m2 (range 18–44 kg/m2)] who satisfied all
criteria and whose clamp study (see below) passed the quality
control check.
Insulin clamp A euglycaemic–hyperinsulinaemic clamp
was performed in all individuals. Exogenous insulin was
administered as a primed-continuous infusion at a rate of
240 pmol min−1 m−2 simultaneously with a variable 20%
(w/v) glucose infusion adjusted every 5–10 min to maintain
plasma glucose levels within 0.8 mmol/l (±15%) of the
target glucose level (4.5–5.5 mmol/l). The clamp procedure
was standardised across centres with the use of a demon-
stration video and operating instructions; the raw data from
each clamp study were immediately transferred to the coor-
dinating centre where they were underwent quality control
scrutiny according to pre-set criteria.
Local Ethics Committee approval was obtained by each
recruiting centre. Volunteers were given detailed written
information on the study and signed a consent form.
Analytical determinations Samples were transported on dry
ice at pre-arranged intervals to central laboratories. Plasma
glucose was measured by the glucose oxidase technique.
Plasma insulin, proinsulin and C-peptide were measured by
a two-site time-resolved fluoroimmunoassay (AutoDELFIA
Insulin kit; Wallac Oy, Turku, Finland) using monoclonal
antibodies, with the following assay characteristics (for
insulin, proinsulin and C-peptide, respectively): sensitivity
1–2, 0.3 and 5 pmol/l, within-assay variation 5, 6 and 5%
and between-assay variation 5, 8 and 3.5%. The glucagon
assay (developed in J. Holst’s laboratory in Copenhagen,
Denmark) is highly specific for the free C terminus of the
molecule, and therefore specific for pancreatic glucagon,
with the following assay characteristics: sensitivity <1 pmol/l,
within-assay CV <5% at 20 pmol/l, between-assay CV <12%.
Serum adiponectin was assayed by a novel, in-house time-
resolved immunofluorimetric method, previously described
in detail [15], which measures total circulating adiponectin
(including high- and low-molecular-mass isoforms).
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Data analysis Glucose tolerance was categorised into
normal, impaired fasting glycaemia (IFG) and IGTaccording
to the American Diabetes Association criteria [16]. IFG and
IGT were grouped together as IGR (n=152 or 11.7% of the
total cohort). Insulin sensitivity was expressed as the ratio
of the M value, averaged over the final 40 min of the 2 h
clamp and normalised for fat-free mass (FFM; measured by
electrical bioimpedance [15]), to the mean plasma insulin
concentration measured during the same interval [M/I, in
units of μmol min−1 kgFFM
−1 (nmol/l)−1] [17].
Statistical analysis Data are reported as means±SD. Variables
(BMI, M/I, hormone concentrations) with a skewed distri-
bution (by a Shapiro–Wilk W test) are given as median and
interquartile range and were logarithmically transformed for
use in statistical testing. Association between two variables
was tested by Spearman rank correlation ρ value. Differences
across groups were tested by a Mann–Whitney or Kruskal–
Wallis test. General linear models were used to test the
simultaneous dependence of continuous variables on multi-
ple parameters; results are presented as the partial regression
coefficient. When multiple logistic regression was applied,
results are given as odds ratio (OR) and 95% CIs. All
multivariate models were adjusted for centre. Statistical
analyses were carried out using JMP Version 3.1 (SAS
Institute, Cary, NC, USA).
Results
Insulin sensitivity (as M/I) was higher in women than men
[145 (interquartile range 82) vs 112 (70) μmol min−1
kgFFM
−1 (pmol/l)−1, p<0.0001] as were fasting adiponectin
concentrations [9.3 (4.9) vs 6.0 (3.1) mg/l, p<0.0001]. In
contrast, fasting serum glucagon [9.0 (5.0) vs 7.0 (3.0)
pmol/l] and proinsulin concentrations [6.0 (5.0) vs 5.0 (3.0)
pmol/l] were higher in men than women (p<0.0001 for
both). Glucagon [9.0 (6.0) vs 8.0 (4.0) pmol/l, p<0.004]
and proinsulin [8.0 (7.0) vs 5.0 (4.0) pmol/l, p<0.0001]
levels were also higher, and adiponectin was lower [6.3
(4.0) vs 7.9 (4.9) mg/l, p<0.0001), in IGR (i.e. IFG or IGT)
individuals, who were also less insulin sensitive than NGT
individuals [93 (73) vs 133 (86) μmol min−1 kgFFM
−1
(pmol/l)−1, p<0.0001].
In either sex, glucagon and proinsulin increased across
sex-specific quartiles of IR, whereas adiponectin displayed
the opposite trend (p≤0.02 for all; Fig. 1). In univariate
analysis using continuous variables, both glucagon and
proinsulin were negatively related to M/I, while adiponectin
was positively associated with it (all p<0.0001; Table 1).
To rule out that these associations might be due to
confounding, determinants of insulin sensitivity (i.e. sex,
age, BMI and glucose tolerance status) as well as factors
potentially affecting glucagon and proinsulin (i.e. fasting
plasma glucose and C-peptide concentrations) were entered
as covariates into multivariate models of the associations
between insulin sensitivity and hormone levels. As shown
by the partial correlation coefficients in Table 1, glucagon and
proinsulin were still negatively associated, and adiponectin
was positively associated, with M/I. From the multiple
regression equation, fasting glucagon in an individual in the
top quartile of IR is estimated to be ∼15% higher than in an
individual in the bottom quartile of IR. When the pro-
insulin:C-peptide ratio was used as the dependent variable
(and fasting C-peptide concentration was removed as an
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Fig. 1 Fasting concentrations of
glucagon, proinsulin, adipo-
nectin and insulin sensitivity
(M/I) in 1,296 non-diabetic men
(green) and women (red) strati-
fied by sex-specific quartile of
insulin sensitivity. Boxes are
median, SD and 95% CIs
2344 Diabetologia (2007) 50:2342–2347
independent variable), the reciprocal relationship with M/I
was still statistically significant.
These associations were also tested in terms of the
probability that individuals in the top sex-specific quartile
of IR (cf. Fig. 1) would have hormone levels in the top sex-
specific quartile of their distribution. The results show that
insulin-resistant individuals were more likely than more
sensitive individuals to have raised glucagon and proinsulin
concentrations [with an OR of ∼2 for both glucagon
(p=0.02) and proinsulin (p=0.05)] and lower adiponectin
levels (OR of 0.36, p<0.0001) independently of co-variates
(Fig. 2). Of interest, obesity (as the BMI) showed signif-
icant associations with relative hyperglucagonaemia, hyper-
proinsulinaemia and hypoadiponectinaemia as IR but
independently of it.
Finally, individuals in the top quartile of fasting glucagon
concentrations had a high chance of also having proinsulin
concentrations in the top quartile (χ2=14.5, p<0.0001).
Discussion
The present analysis demonstrates that in a non-diabetic
population IR is associated with raised fasting plasma pan-
creatic glucagon and proinsulin concentrations. Adiponectin,
which was used as a positive control, showed the expected
reciprocal association with IR. These associations were
independent of factors, such as sex, age, BMI and glucose
tolerance, known to affect insulin action. Also, the multivar-
iate statistical models included fasting glucose and C-peptide
concentrations: the former to account for the tonic influence
of glucose on both insulin and glucagon release, the latter to
adjust proinsulin and glucagon levels for the concomitant
rate of insulin secretion. Finally, the relationships were
statistically significant whether using continuous or categor-
ical variables to best control for the non-normal distribution
of most variables.
The physiological implication of these findings may be
that IR extends to both alpha cells and beta cells in the
islets of Langerhans. In alpha cells, IR translates into a
reduced tonic inhibition of glucagon release, resulting in
inappropriately (for the concomitant glucose levels) raised
glucagon concentrations. In beta cells, IR translates into
defective proinsulin to insulin secretory coupling, resulting
in inappropriately (for the concomitant C-peptide and
glucose levels) raised proinsulin concentrations.
In isolated rat pancreatic alpha cells, glucose, like
arginine and tolbutamide, stimulates glucagon release by
closing the KATP channel, an effect that is abolished by the
KATP-channel opener, diazoxide, by N-type Ca
2+-channel
blockers or by inhibitors of glycolysis and mitochondrial
metabolism [18]. Therefore, the suppressive effect of
glucose on glucagon secretion in intact islets and in vivo
results entirely from paracrine signalling; as alpha cells are
rich in insulin receptors, insulin is the foremost paracrine
candidate (somatostatin being another potentially important
mediator). The cellular mechanisms by which insulin exerts
a tonic inhibition on alpha cell function involve, but are
not limited to, activation of KATP channels [19]. Our finding
of an independent association of IR with relative fasting
hyperglucagonaemia in non-diabetic individuals implies
such a physiological control mechanism, but does not rule
out that the feedback may be mediated by changes in
circulating nutrients. For example, IR is associated with
raised plasma concentrations of NEFAs and branched-chain
amino acids [20]. In the current database, NEFAs were not
an independent correlate of plasma glucagon (data not
shown), but aminoacidaemia was not measured. Also, the
association of glucagon levels with IR might stand for an
effect of glucagon on insulin sensitivity rather than the other
way around. Although in human studies glucagon has not
Age
BMI
IGR vs NGT
Fasting glucose
Fasting C-peptide
Insulin resistance
0.1 1 7
OR (95% CI)
Fig. 2 Multivariate ORs for the association of IR (bottom sex-specific
quartile of M/I) with fasting concentrations of plasma glucagon
(green), proinsulin (red) and adiponectin (blue) in the respective top
quartile of their distribution. ORs of continuous co-variates are
calculated for 1 SD of the entire cohort
Table 1 Associations of insulin sensitivity (M/I) with fasting
hormone levels
Glucagon Proinsulin Proinsulin:
C-peptide
Adiponectin
Univariate
associationa
−0.22 −0.44 −0.15 0.38
Multivariate
associationb
−0.05 −0.23 −0.12 0.19
Total
explained
variance
0.43 0.49 0.13 0.39
a Spearman ρ
b Partial r adjusted for centre, sex, age, BMI, fasting glucose and glucose
tolerance
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been shown to interfere with insulin-mediated glucose
uptake [21], recent experiments in dogs have shown that
chronic hyperglucagonaemia impairs both hepatic and
peripheral tissue glucose uptake [22].
The above considerations largely apply also to the ob-
served association between IR and hyperproinsulinaemia.
The cellular basis of this association is equally robust. Mice
with beta cell-specific knockout of insulin receptors show a
loss of first-phase insulin release reminiscent of typical
human type 2 diabetes [23], and lack of functional insulin
and IGF-1 receptors in beta cells leads to age-related reduc-
tion in beta cell mass, severe beta cell dysfunction and overt
diabetes [24]. Together, genetic and physiological data
provide evidence that insulin signalling in beta cells is
important for competent beta cell functioning.
Of further interest is the independent association of obesity
(as the BMI) with raised fasting glucagon and proinsulin
concentrations after controlling for both IR and fasting
C-peptide (Fig. 2). This previously unrecognised finding
suggests that obesity per se imposes a secretory strain on the
islet that is independent of the adaptive response to IR. We
have previously shown that the insulin hypersecretion of
obesity is only in part due to the concomitant IR: for the
greater part, it is primary and reverses with weight loss [25,
26]. The current data are compatible with the view that such
a stressful effect of obesity involves alpha cells as well as
beta cells [12], and may underlie the strong predictivity of
obesity for incident diabetes [27].
In summary, whole-body IR is independently associated
with raised fasting plasma glucagon and proinsulin con-
centrations, possibly as a result of IR at the level of alpha
cells and beta cells in pancreatic islets.
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